MDASI-CML symptom and interference items: the difference between treatment arms in change from baseline scores.
nausea, diarrhea, vomiting, pain, −1.7, dry mouth
DRY MOUTH, LACK OF APPETITE
CI = confidence interval, LS Mean=least squares mean. LS mean (95% CI) for difference in change from baseline scores between treatment arms. Dashed lines = clinically meaningful differences (green in favor of asciminib; blue in favor of bosutinib).The difference in change from baseline scores between treatments shows a greater decrease in the symptom severity score, symptom distress score, and in almost all individual symptom and interference items for patients randomized to asciminib treatment compared to bosutinib treatment (LS mean difference <0 favors patients treated with asciminib), although most differences in scores did not reach a clinically meaningful difference (based on MID of 1.5 points). The greatest reported mean (95% CI) differences between treatment arms in favor of asciminib were in the symptom items of diarrhea (−1.7 [−2.2, −1.3]), nausea (−1.2 [−1.7, −0.8]), lack of appetite (−0.8 [−1.2, −0.4]), vomiting (−0.6 [−1.0, −0.3]), feeling drowsy (−0.6 [−1.2, −0.1]), dry mouth (−0.6 [−1.1, −0.1]), and pain (−0.6 [−1.1, −0.0]). Among the symptom items, diarrhea had the greatest difference in score between treatment arms of −1.7 points (indicating a clinically meaningful difference based on the MID of 1.5 points), which was driven by the increase in diarrhea severity reported by patients in the bosutinib treatment arm (Supplementary Table 